Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ AXSM (Common Stock) $5.50 + 0.10 (1.85%)
Stock chart for: AXSM.O.  Currently trading at $5.50 with a 52 week high of $9.11 and a 52 week low of $3.53.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors

June 19, 2017NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Myrtle Potter to its Board of Directors. Ms. Potter is the Chief Executive Officer and Founder of Myrtle Potter & Company, a healthcare and life science advisory firm. Ms. Potter previously served as the President, Commercial Operations and Chief... 

Axsome Therapeutics Reports First Quarter 2017 Financial Results

May 9, 2017NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended March 31, 2017. “In the first quarter we continued to advance all of our clinical programs, which include three ongoing Phase 3 trials with our lead product candidates AXS-02 and AXS-05,” said Herriot Tabuteau, M.D., Chief E... 

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation

May 8, 2017NEW YORK, May 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for AXS-05 for the treatment of agitation in patients with Alzheimer’s disease (AD). There are currently no approved treatments for this condition. Axsome previously received Investigational New Drug A...